

<p>1. INTRODUCTIONS</p> <p><i>a. Welcoming new working group members</i></p> <p><i>i. Airton Stein, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Brazil</i></p> <p><i>Participants:</i> <i>Airton Stein</i> <i>Birte Smilstveit</i> <i>David Gough</i> <i>Gabriel Rada</i> <i>Jeremy Grimshaw</i> <i>Kayongo Edward</i> <i>Lucy Nakibuuka</i> <i>Ocan Moses</i> <i>Safa Al-Khateeb</i></p>	<p>3 min</p>
<p>2. FOLLOW-UP ON ACTION ITEMS</p> <p><i>Not applicable</i></p>	<p>min</p>
<p>3. COVID-END COMMENTARY ON LMIC PERSPECTIVES</p> <p><i>a. Updates on draft paper</i></p> <ul style="list-style-type: none"> • <i>Ruth circulated a draft last week to Jeremy and Lucy</i> • <i>Approached Lancet editor Jocelyn Clark, who had stated that currently there are a lot of papers being submitted and had advised that COVID-END submit the paper regardless</i> <p><i>b. Next steps</i></p> <ul style="list-style-type: none"> • ACTION: <i>Jeremy to work on the draft with Ruth for this week and circulate it back to authors/partners that are involved</i> • ACTION: <i>Submit to Lancet</i> • <i>Paper will have group authorship from LMIC partners that provided contributions/perspectives</i> 	<p>25 min</p>
<p>4. DISCUSSION OF COVID-END MID-TERM PROJECTS</p> <p><i>a. Sustainability of COVID-END in the next phase</i></p> <ul style="list-style-type: none"> • <i>Gone through the first wave of COVID-19 globally, and there has been a significant upsurge in evidence synthesis and duplication of efforts and rapid reviews.</i> 	<p>30 min</p>

<ul style="list-style-type: none"> • <i>During the first phase of COVID-19, COVID-END was trying to get different groups/organisations at the table and coordinate work that includes inventory of resources, packaging of resources to inform decision-making and sharing those resources between partners</i> • <i>In the next phase, is there an approach that reduces the noise in the evidence synthesis community and ensure better coordination of better quality syntheses at the international level</i> <ul style="list-style-type: none"> ○ <i>Working Group members to think about how Scoping can work with partners to try and identify priorities for living reviews</i> ○ <i>Horizon scanning process to try and better predict future evidence synthesis needs in order to be proactive than reactive</i> • <i>It will be continually necessary moving forward to establish trust with all of the different partners and ensure that the work the partners are producing is useful and can be disseminated (maximum advantage can be taken from those initiatives and products). Transmission of information needs to be optimal as some partners may feel that they do not have the space to showcase or disseminate their work</i> • <i>A potential approach to stimulate longer term COVID-END engagement is to identify successes and failures in the local communities of partners</i> • <i>Jeremy raised a point on the extent that COVID-END can make in guiding statements and highlighting issues in the duplication of efforts and quality (in which COVID-END does not have a mandating role) and ensuring that there is equal (and equitable) production of high quality global evidence in the global North and South</i> • <i>David Gough highlighted that COVID-END is providing a concrete example of collaborative partnerships in the COVID-19 global community and that for potential next steps or approaches, COVID-END can think about social policy and the effectiveness of current methods and measures in capturing inequity</i> • ACTION: Every 3rd Scoping WG meeting, discussion around sustainability will be revisited as an agenda item <p><i>b. Sharing of lessons learned and insights from health sector to non-health sector</i></p> <ul style="list-style-type: none"> • ACTION: Working Group members to think about this point for our next discussion 	
<p>5. ANY OTHER BUSINESS</p>	<p>2 min</p>